These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 29656280)

  • 1. Real-World Bioresorbable Vascular Scaffold Experience Compared With Second-Generation Metallic Drug-Eluting Stents in Complex Coronary Lesions.
    Okamoto N; Ueda H; Yoshimura T; Chamaria S; Bhatheja S; Vengrenyuk Y; Rabiei S; Barrientos Y; Kapur V; Barman N; Sweeny J; Baber U; Mehran R; Sharma SK; Kini AS
    J Invasive Cardiol; 2018 Jul; 30(7):251-255. PubMed ID: 29656280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ABSORB biodegradable stents versus second-generation metal stents: a comparison study of 100 complex lesions treated under OCT guidance.
    Mattesini A; Secco GG; Dall'Ara G; Ghione M; Rama-Merchan JC; Lupi A; Viceconte N; Lindsay AC; De Silva R; Foin N; Naganuma T; Valente S; Colombo A; Di Mario C
    JACC Cardiovasc Interv; 2014 Jul; 7(7):741-50. PubMed ID: 25060016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of acute expansion of bioresorbable vascular scaffolds versus metallic drug-eluting stents in different degrees of calcification: An Optical Coherence Tomography Study.
    Ming Fam J; van Der Sijde JN; Karanasos A; Felix C; Diletti R; van Mieghem N; de Jaegere P; Zijlstra F; Jan van Geuns R; Regar E
    Catheter Cardiovasc Interv; 2017 Apr; 89(5):798-810. PubMed ID: 27717119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fate of post-procedural malapposition of everolimus-eluting polymeric bioresorbable scaffold and everolimus-eluting cobalt chromium metallic stent in human coronary arteries: sequential assessment with optical coherence tomography in ABSORB Japan trial.
    Sotomi Y; Onuma Y; Dijkstra J; Miyazaki Y; Kozuma K; Tanabe K; Popma JJ; de Winter RJ; Serruys PW; Kimura T
    Eur Heart J Cardiovasc Imaging; 2018 Jan; 19(1):59-66. PubMed ID: 28158421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Head-to-head comparison of the neointimal response between metallic and bioresorbable everolimus-eluting scaffolds using optical coherence tomography.
    Gomez-Lara J; Brugaletta S; Farooq V; Onuma Y; Diletti R; Windecker S; Thuesen L; McClean D; Koolen J; Whitbourn R; Dudek D; Smits PC; Chevalier B; Regar E; Veldhof S; Rapoza R; Ormiston JA; Garcia-Garcia HM; Serruys PW
    JACC Cardiovasc Interv; 2011 Dec; 4(12):1271-80. PubMed ID: 22192368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is high pressure postdilation safe in bioresorbable vascular scaffolds? Optical coherence tomography observations after noncompliant balloons inflated at more than 24 atmospheres.
    Fabris E; Caiazzo G; Kilic ID; Serdoz R; Secco GG; Sinagra G; Lee R; Foin N; Di Mario C
    Catheter Cardiovasc Interv; 2016 Apr; 87(5):839-46. PubMed ID: 26370357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optical coherence tomography-guided versus angiography-guided implantation of everolimus-eluting bioresorbable vascular scaffolds: Comparison of coverage, apposition and clinical outcome. The ALSTER-OCT ABSORB registry.
    Heeger CH; Schedifka AS; Meincke F; Spangenberg T; Wienemann H; Kreidel F; Kuck KH; Ghanem A; Bergmann MW
    Cardiol J; 2018; 25(4):459-469. PubMed ID: 29512092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of early clinical outcomes between ABSORB bioresorbable vascular scaffold and everolimus-eluting stent implantation in a real-world population.
    Costopoulos C; Latib A; Naganuma T; Miyazaki T; Sato K; Figini F; Sticchi A; Carlino M; Chieffo A; Montorfano M; Colombo A
    Catheter Cardiovasc Interv; 2015 Jan; 85(1):E10-5. PubMed ID: 24909303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial.
    Onuma Y; Sotomi Y; Shiomi H; Ozaki Y; Namiki A; Yasuda S; Ueno T; Ando K; Furuya J; Igarashi K; Kozuma K; Tanabe K; Kusano H; Rapoza R; Popma JJ; Stone GW; Simonton C; Serruys PW; Kimura T
    EuroIntervention; 2016 Oct; 12(9):1090-1101. PubMed ID: 27597270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiographic and optical coherence tomography insights into bioresorbable scaffold thrombosis: single-center experience.
    Karanasos A; Van Mieghem N; van Ditzhuijzen N; Felix C; Daemen J; Autar A; Onuma Y; Kurata M; Diletti R; Valgimigli M; Kauer F; van Beusekom H; de Jaegere P; Zijlstra F; van Geuns RJ; Regar E
    Circ Cardiovasc Interv; 2015 May; 8(5):. PubMed ID: 25969547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design.
    Diletti R; Serruys PW; Farooq V; Sudhir K; Dorange C; Miquel-Hebert K; Veldhof S; Rapoza R; Onuma Y; Garcia-Garcia HM; Chevalier B
    Am Heart J; 2012 Nov; 164(5):654-63. PubMed ID: 23137495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds.
    Puricel S; Arroyo D; Corpataux N; Baeriswyl G; Lehmann S; Kallinikou Z; Muller O; Allard L; Stauffer JC; Togni M; Goy JJ; Cook S
    J Am Coll Cardiol; 2015 Mar; 65(8):791-801. PubMed ID: 25720622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of strut thickness on acute mechanical performance: A comparison study using optical coherence tomography between DESolve 150 and DESolve 100.
    Boeder NF; Dörr O; Bauer T; Mattesini A; Elsässer A; Liebetrau C; Achenbach S; Hamm CW; Nef HM
    Int J Cardiol; 2017 Nov; 246():74-79. PubMed ID: 28579164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twelve-Month Outcomes With a Bioresorbable Everolimus-Eluting Scaffold: Results of the ESHC-BVS Registry at Two Australian Centers.
    Robaei D; Back L; Ooi SY; Pitney M; Jepson N
    J Invasive Cardiol; 2016 Aug; 28(8):316-22. PubMed ID: 26567454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expansion and malapposition characteristics after bioresorbable vascular scaffold implantation.
    Brown AJ; McCormick LM; Braganza DM; Bennett MR; Hoole SP; West NE
    Catheter Cardiovasc Interv; 2014 Jul; 84(1):37-45. PubMed ID: 24403223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanical properties of the everolimus-eluting bioresorbable vascular scaffold compared to the metallic everolimus-eluting stent.
    Dalos D; Gangl C; Roth C; Krenn L; Scherzer S; Vertesich M; Lang I; Maurer G; Neunteufl T; Berger R; Delle-Karth G
    BMC Cardiovasc Disord; 2016 May; 16():104. PubMed ID: 27225486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials.
    Muramatsu T; Onuma Y; García-García HM; Farooq V; Bourantas CV; Morel MA; Li X; Veldhof S; Bartorelli A; Whitbourn R; Abizaid A; Serruys PW;
    JACC Cardiovasc Interv; 2013 Mar; 6(3):247-57. PubMed ID: 23517836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mid-term clinical outcomes of ABSORB bioresorbable vascular scaffold versus everolimus-eluting stent for coronary bifurcation lesions.
    Naganuma T; Kawamoto H; Panoulas VF; Latib A; Tanaka A; Mitomo S; Ruparelia N; Jabbour RJ; Chieffo A; Carlino M; Montorfano M; Colombo A
    Int J Cardiol; 2017 Nov; 246():26-31. PubMed ID: 28867010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coronary artery perforation at the level of two-overlapping bioresorbable vascular scaffolds: The importance of vessel sizing and scaffold thickness.
    Pichette M; Chevalier F; Généreux P
    Catheter Cardiovasc Interv; 2015 Oct; 86(4):686-91. PubMed ID: 26122768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.